Clinical Trials Logo
  1. Home
  2. Cutaneous Lupus Erythematosus
  3. NCT00317681

Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus Clinical Trial

Official title:
The Efficacy of Topical Tacrolimus in the Treatment of Cutaneous Lupus Erythematosus - a Multi-Center-Trial

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of topical tacrolimus in different subtypes of cutaneous lupus erythematosus. As shown by several groups activated memory T lymphocytes play a key role in the pathogenesis of lupus erythematosus. Tacrolimus targets T lymphocytes and suppresses their activation by inhibiting the expression of cytokine genes, such as IL-2. Therefore, treatment of cutaneous lupus erythematosus with topical tacrolimus might result in an improvement of skin lesions in such patients.

Clinical Trial Description

In patients with cutaneous lupus erythematosus (CLE), topical corticosteroids are the mainstay of treatment; however, a long-term use can lead to numerous side effects including skin atrophy. Recently, topical tacrolimus has been suggested to be effective in patients with different manifestations of CLE as single or additive therapy. Its anti-inflammatory effect can be explained by inhibition of calcineurin and suppression of proinflammatory cytokines such as interleukins-2, -3, -4, granulocyte colony-stimulating factor, and tumour necrosis factor alpha. In this study, we evaluate the efficacy of tacrolimus in 30 patients with different forms of CLE (ACLE, SCLE, DLE, LET). During a period of 3 months tacrolimus ointment and its placebo are applied on two separate skin lesions. Clinical follow-up examinations including photo documentation are performed every 4 weeks. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00317681
Study type Interventional
Source Heinrich-Heine University, Duesseldorf
Contact
Status Completed
Phase Phase 2
Start date August 2005
Completion date February 2007
View Details
See also
  Status Clinical Trial Phase
Completed NCT01776190 - Low-dose UVA1 Radiation in Cutaneous Lupus Patients N/A
Completed NCT00420173 - Interdisciplinary Study Group of Lupus Erythematosus (ISGLE) N/A
Terminated NCT04809623 - Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) Phase 1
Completed NCT01300208 - To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus Phase 2
Terminated NCT01470313 - A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus Phase 1
Completed NCT01146444 - Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE) N/A
Completed NCT03134222 - Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Phase 2
Completed NCT01629784 - Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus N/A
Completed NCT00470912 - Sunscreen RV 2457C in Photoinduced CLE Phase 3
Completed NCT01841619 - IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus Phase 0
Completed NCT00523588 - Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser Phase 2
Recruiting NCT06411106 - Deep Phenotyping of Cutaneous Lupus Erythematosus N/A
Not yet recruiting NCT06015737 - A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Phase 3
Terminated NCT01498406 - Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus Phase 2
Completed NCT04647708 - Study of M5049 in CLE and SLE Participants Phase 1
Completed NCT03817424 - A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis Phase 1
Active, not recruiting NCT03260166 - Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus Phase 2
Completed NCT04781816 - Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus Phase 2